PNC-27 vs NAD+
Side-by-side comparison of key properties, dosing, and research.
- Summary
- PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
- NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells that declines dramatically with age. It is critical for energy metabolism, DNA repair, and sirtuin activation. IV and subcutaneous NAD+ supplementation is used in anti-aging protocols and addiction recovery programs.
- Half-Life
- Not well established; estimated minutes to hours
- Varies by route; IV provides direct cellular delivery
- Admin Route
- Intravenous (research), Intraperitoneal (research)
- IV, SubQ, Oral
- Research
- —
- —
- Typical Dose
- Not established for humans; research doses vary by cell line and model
- 500–1000 mg
- Frequency
- Not established for human use
- Daily for 4–10 days (loading), then monthly maintenance
- Key Benefits
- Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
- Spares normal cells lacking surface HDM2 expression
- Membranolytic mechanism bypasses intracellular resistance pathways
- Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
- Potential for combination with conventional chemotherapy
- Novel non-genotoxic anticancer mechanism
- Restored cellular energy production (ATP)
- Sirtuin activation for longevity and metabolic regulation
- Enhanced DNA repair capacity
- Improved mitochondrial function and biogenesis
- Cognitive clarity and mental energy
- Reduced inflammation
- Addiction withdrawal support (opioids, alcohol, benzodiazepines)
- Improved sleep quality
- Enhanced athletic endurance
- Side Effects
- Limited human clinical data; largely in vitro and animal studies
- Potential immunogenic reactions (foreign peptide)
- Systemic toxicity at high doses not well characterized
- Unknown interactions with current chemotherapy agents
- Flushing and warmth during IV infusion
- Nausea during rapid IV administration
- Chest tightness (from rapid infusion — slow the rate)
- Injection site irritation (subcutaneous)
- +1 more
- Stacks With
- —
- —